The five-year survival rate in patients with systemic ALK-positive ALCL is 70 to 80 percent but only 15 to 45 percent in patients with systemic ALK-negative ALCL. For primary cutaneous ALCL, prognosis is good if there is not extensive involvement of the skin, with five-year survival rates of approximately 90 percent. Breast implant–associated ALCL has an excellent prognosis when the lymphoma is confined to the fluid or to the capsule surrounding the breast implant. This tumor can be recurrent and grow as a mass around the implant capsule or can extend to regional lymph nodes if not properly treated.